Valuation: GENinCode Plc

Market Cap 6.02M 8.07M 7.06M 6.51M 11.43M 770M 11.63M 77.97M 30.57M 378M 30.3M 29.64M 1.31B P/E 2026 *
-1.14x
P/E 2027 * -
Enterprise Value 5.22M 7M 6.12M 5.65M 9.92M 668M 10.08M 67.62M 26.51M 328M 26.28M 25.71M 1.14B EV / Sales 2026 *
1.1x
EV / Sales 2027 * -
Free-Float
59.68%
Yield 2026 *
-
Yield 2027 * -
1 week-13.98%
Current month-13.98%
1 month-20.00%
3 months-27.27%
6 months-58.97%
Current year-66.67%
1 week 0.78
Extreme 0.785
0.95
1 month 0.78
Extreme 0.785
1.1
Current year 0.78
Extreme 0.785
2.5
1 year 0.78
Extreme 0.785
5.5
3 years 0.78
Extreme 0.785
14
5 years 0.78
Extreme 0.785
48
10 years 0.78
Extreme 0.785
48
Manager TitleAgeSince
Chief Executive Officer 62 2018-09-05
Chief Operating Officer 51 2018-09-05
Director of Finance/CFO 57 2020-10-31
Director TitleAgeSince
Director/Board Member 57 2021-03-31
Chairman 62 2018-09-05
Chairman 72 2020-12-31
Date Insider Type Main position Quantity % Market Cap.
05-05Free

Chief Financial Officer

13,523,757 1.7959%
05-05Free

Founder

30,428,453 4.0407%
05-05Free

Director

1,267,852 0.1684%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-13.98%-57.89%-93.19% 8.05M
+5.06%-2.32%+221.47%+341.19% 20.71B
+3.62%+1.49%-40.14%-21.18% 9.3B
-0.71%-3.55%+26.95%+28.63% 6.95B
+3.18%-2.35%-34.40% - 4.9B
+1.77%-4.95%-24.40%-31.76% 4.77B
+15.03%+10.48%+256.20%-20.04% 4.76B
0.00%+0.23%-22.58%-24.00% 4.02B
-2.10%-13.10%+59.98%+68.87% 3.67B
-0.91%+1.46%-18.82%-40.91% 2.59B
Average +2.49%-5.28%+36.64%+23.07% 6.17B
Weighted average by Cap. +3.55%-4.86%+87.79%+121.00%

Financials

2026 *2027 *
Net sales 4.73M 6.34M 5.55M 5.11M 8.98M 605M 9.13M 61.25M 24.01M 297M 23.8M 23.29M 1.03B -
Net income -5.02M -6.72M -5.88M -5.42M -9.53M -642M -9.69M -64.96M -25.47M -315M -25.24M -24.7M -1.09B -
Net Debt -800K -1.07M -938K -865K -1.52M -102M -1.54M -10.35M -4.06M -50.24M -4.02M -3.94M -174M -
Logo GENinCode Plc
GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
Employees
44
Date Price Change Volume
26-07-09 GBX 0.8000 0.00% 5,612,694
26-07-08 GBX 0.8000 -8.57% 3,089,034
26-07-07 GBX 0.8750 -2.78% 5,825,781
26-07-06 GBX 0.9000 0.00% 563,670
26-07-03 GBX 0.9000 -3.23% 6,541,873
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.008000GBP
Average target price
0.0750GBP
Spread / Average Target
+837.50%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENI Stock